Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Trials of semaglutide in patients with Alzheimer’s and CagriSema in obese patients diabetes could give investors reason to be ...

Stocks in Europe ended Monday's session slightly higher, as investors reacted to more disappointing economic news out of the ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of ...

Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 22% on Friday after reporting results in a late-stage ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 22% on Friday after reporting results in a late-stage ...

Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...

Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...

Novo traded down more than 20% Friday morning, its biggest loss since 2002. The CagriSema news boosted competitors, such as ...

The Danish company has announced positive results from its Phase III trial of CagriSema but fell short of a previously ...